http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#Head http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#assertion http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#provenance http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#pubinfo http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#assertion http://purl.obolibrary.org/obo/DOID_13884 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_13884 http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00343 http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association http://www.w3.org/2000/01/rdf-schema#label "Diltiazem hydrochloride injection is contraindicated in: Patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker. Patients with second- or third-degree AV block except in the presence of functioning ventricular pacemaker. Patients with severe hypotension or cardiogenic shock. Patients who have demonstrated hypersensitivity to the drug. Intravenous diltiazem and intravenous beta-blockers should not be administered together or in close proximity (within a few hours). Patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in WPW syndrome or short PR syndrome. As with other agents which slow AV nodal conduction and do not prolong the refractoriness of the accessory pathway (eg, verapamil, digoxin), in rare instances patients in atrial fibrillation or atrial flutter associated with an accessory bypass tract may experience a potentially life-threatening increase in heart rate accompanied by hypotension when treated with diltiazem hydrochloride injection. As such, the initial use of diltiazem hydrochloride injection should be, if possible, in a setting where monitoring and resuscitation capabilities, including DC cardioversion/defibrillation, are present (see OVERDOSAGE Patients with ventricular tachycardia. Administration of other calcium channel blockers to patients with wide complex tachycardia (QRS >= 0.12 seconds) has resulted in hemodynamic deterioration and ventricular fibrillation. It is important that an accurate pretreatment diagnosis distinguish wide complex QRS tachycardia of supraventricular origin from that of ventricular origin prior to administration of diltiazem hydrochloride injection." http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB00343 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#provenance http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#pubinfo http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#sig http://purl.org/nanopub/x/hasSignature GM1ebHORQSOLl0aXAdpMD9ZSDIBqY6ZVfNwWF1g37P6NzKhLxzAyywrpzAFG4/KbSCbRaBX/UzBhDAEMqh6H3dC1D+bMZ7JNj0NFtzWrJxVgbP336vDODnxNeOZ2B9EYjPLcxAg8yyG43/T4RSt2Vto3p5IfVUcFZwhNJUIuT0M= http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo http://purl.org/dc/terms/created 2021-08-23T12:31:18.871+02:00 http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAWjyO26-GRMR1Uo3OjJNzj9mXncAj2BM5SLfeYHQYCRo https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY